Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …

The advent of precision medicine has brought light to the treatment of non-small cell lung
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …

Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …

Background The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved
for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

PURPOSE Genetic rearrangements of the tyrosine receptor kinase ROS proto-oncogene 1
(ROS1) are oncogenic drivers in non-small-cell lung cancer (NSCLC). We report the results …

The mammalian spermatozoa produced in the testis require functional maturation in the
epididymis for their full competence. Epididymal sperm maturation is regulated by lumicrine …

Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor
tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is …

Oncogenes that occur in≤ 5% of non-small-cell lung cancers have been defined as 'rare';
nonetheless, this frequency can correspond to a substantial number of patients diagnosed …

The ROS-1 gene plays a major role in the oncogenesis of numerous tumors. ROS-1
rearrangement is found in 0.9–2.6% of non-small-cell lung cancers (NSCLCs), mostly lung …